Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
argenx SEBSP:A1RG34 -0.37%75 3-1 Month Momentum % is 16.43% as of Sep. 21, 2026. GuruFocus rates BSP:A1RG34 with a GF Score™ of 75/100 and a GF Value™ of R$328.84 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, argenx SE ranks better than 72.4% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), argenx SE's 3-1 Month Momentum % is 16.43%.
The industry rank for argenx SE's 3-1 Month Momentum % or its related term are showing as below:
BSP:A1RG34's 3-1 Month Momentum % is ranked better than 72.4% of 1384
companies
in the Biotechnology industry
Industry Median: 0.44
vs BSP:A1RG34: 16.43
argenx SE (BSP:A1RG34) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
argenx SE 3-1 Month Momentum % Related Terms
BSP:A1RG34 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, argenx SE's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where argenx SE's 3-1 Month Momentum % falls into.
argenx SE (BSP:A1RG34) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (BSP:A1RG34) has a 3-1 Month Momentum % of 16.43% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #382 out of 1384 companies in the Biotechnology industry, placing it in the top 27.6%.
Is argenx SE's 3-1 Month Momentum % too high?
argenx SE's current 3-1 Month Momentum % is 16.43%. The Biotechnology industry median 3-1 Month Momentum % is 0.44. argenx SE's value of 16.43% is 3634.1% above this industry median. Based on the distribution chart, argenx SE ranks #382 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, argenx SE has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #382 out of 1384 companies for 3-1 Month Momentum %. This puts argenx SE in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.44. argenx SE's value of 16.43% is 3634.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.44, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current 3-1 Month Momentum % of 16.43% is 3634.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current 3-1 Month Momentum % is 16.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (BSP:A1RG34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$328.84, compared to a current price of R$204.65 — trading 37.8% below its estimated fair value. The current 3-1 Month Momentum % is 16.43% and 3634.1% above the Biotechnology industry median of 0.44. argenx SE's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For argenx SE (BSP:A1RG34), the current 3-1 Month Momentum % is 16.43% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (BSP:A1RG34) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of R$204.65 is trading 37.8% below its estimated GF Value™ of R$328.84.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for BSP:A1RG34:
3-1 Month Momentum %: 16.43%
GF Value™: R$328.84 vs. price of R$204.65 (37.8% below fair value)
Industry Position: 3634.1% above the Biotechnology median (#382 of 1384)
No single metric tells the full story. See the BSP:A1RG34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
75GF Score
Get the complete analysis for BSP:A1RG34
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:A1RG34 has been successfully added to your 
